The purpose of this case-control study is to assess the contributions of neurocarcinogen exposure and of glutathione S-transferase, cytochrome P-450, and DNA repair genes to the development and genetic susceptibility of brain tumors and to study the effect of these polymorphisms on treatment outcome and toxicity. Studies to date suggest a moderate to large effect for GSTT1 in selected tumor subtypes. We are targeting obtaining data on approximately 1000 cases and controls, with an adequate number of glioblastomas (n=430), astrocytomas (n=300), oligodendrogliomas (n=100) and meningiomas (n=150) to evaluate this hypothesis with reasonable power for relative risks previously reported for GSTT1. All study subjects will be asked to complete a web-based self-administered or telephone-based questionnaire and to provide blood and/or buceal samples for DNA analysis. Research nurses at Duke University Cancer Center (DUCC)/Evanston Hospital will recruit approximately 770/220 recently diagnosed cases (within 3 months) over a 4-year period. An equal number of friend controls will be identified by asking cases to distribute packets of information to 5 friends of the same age (+/- 5 yrs), gender and race. Controls will return interest cards or phone the research nurse to express interest, then complete the protocol at a clinic appointment or using a distance based protocol. Medical records for cases will be reviewed to obtain clinical and treatment information for the survival and toxicity analyses. Linkage with the National Death Index in Year 4 will obtain vital statistics for up to 3 years of follow-up time to assess outcomes. Study coordination and survey data management will be completed at UIC; molecular analysis will be conducted at DUCC. DUCC will facilitate the neuropathology review, provide management support and some local data collection, and store the remaining specimens in their central respository. Data analysis files will be compiled at Duke University and distributed to the PI's at Duke and UIC. Statistical analyses will use conditional logistic regression models appropriate to each specific aim.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA108786-03
Application #
7286330
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2006-09-01
Budget End
2007-08-31
Support Year
3
Fiscal Year
2006
Total Cost
$326,951
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Kurmasheva, Raushan T; Kurmashev, Dias; Reynolds, C Patrick et al. (2018) Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 65:
Lock, Richard; Carol, Hernan; Maris, John M et al. (2017) Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Pediatr Blood Cancer 64:
Kurmasheva, Raushan T; Sammons, Melissa; Favours, Edward et al. (2017) Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 64:
Kurmasheva, Raushan T; Gorlick, Richard; Kolb, E Anders et al. (2017) Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 64:
Attiyeh, Edward F; Maris, John M; Lock, Richard et al. (2016) Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. Pediatr Blood Cancer 63:276-86
Gorlick, Richard; Kolb, E Anders; Keir, Stephen T et al. (2016) Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 63:443-50
Kang, Min H; Reynolds, C Patrick; Kolb, E Anders et al. (2016) Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 63:1744-52
Smith, Malcolm A; Hampton, Oliver A; Reynolds, C Patrick et al. (2015) Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer 62:91-8
Krishnamachari, Bhuma; Il'yasova, Dora; Scheurer, Michael E et al. (2015) A pooled multisite analysis of the effects of atopic medical conditions in glioma risk in different ethnic groups. Ann Epidemiol 25:270-4
Sayour, Elias J; McLendon, Pat; McLendon, Roger et al. (2015) Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother 64:419-27

Showing the most recent 10 out of 178 publications